北京医学
北京醫學
북경의학
BEIJING MEDICAL JOURNAL
2014年
3期
177-179
,共3页
肝硬化%顽固性腹水%腹水浓缩回输%补气活血利水方
肝硬化%頑固性腹水%腹水濃縮迴輸%補氣活血利水方
간경화%완고성복수%복수농축회수%보기활혈이수방
Liver cirrhosis%Refractory ascites%Concentrated ascites reinfusion%Buqi huoxue lishui decoction
目的：评价补气活血利水方药联合自体腹水超滤浓缩回输治疗肝硬化顽固性腹水的临床疗效。方法将90例乙肝肝硬化合并顽固性腹水患者随机分为观察组与对照组，每组45例，均接受常规治疗和腹水浓缩回输治疗，观察组患者加用补气活血利水方药。结果观察组和对照组的总有效率分别为88.9%和64.4%（P <0.05）。治疗后，观察组较对照组的丙氨酸氨基转移酶[（44.40±13.10)U/L vs.（56.90±15.50）U/L]、白蛋白[（33.04±3.13）g/L vs.（30.94±3.52）g/L]、总胆红素[（39.04±8.13）μmol/L vs.（52.94±9.52）μmol/L]、直接胆红素[（16.04±4.13）μmol/L vs.（19.94±5.52）μmol/L]、胆碱酯酶[（3043.55±141.23）mmol/L vs.（2894.42±169.52）mmol/L]明显改善，差异有统计学意义（P <0.05）；肾功能的差异无统计学意义（P >0.05）。组内比较，治疗后各项指标均明显好于治疗前（P <0.05）。发热、肝性脑病、血压下降等不良反应发生率也无明显差异（P >0.05）。结论补气活血利水方联合腹水浓缩回输治疗可以明显提高肝硬化顽固性腹水的临床疗效。
目的：評價補氣活血利水方藥聯閤自體腹水超濾濃縮迴輸治療肝硬化頑固性腹水的臨床療效。方法將90例乙肝肝硬化閤併頑固性腹水患者隨機分為觀察組與對照組，每組45例，均接受常規治療和腹水濃縮迴輸治療，觀察組患者加用補氣活血利水方藥。結果觀察組和對照組的總有效率分彆為88.9%和64.4%（P <0.05）。治療後，觀察組較對照組的丙氨痠氨基轉移酶[（44.40±13.10)U/L vs.（56.90±15.50）U/L]、白蛋白[（33.04±3.13）g/L vs.（30.94±3.52）g/L]、總膽紅素[（39.04±8.13）μmol/L vs.（52.94±9.52）μmol/L]、直接膽紅素[（16.04±4.13）μmol/L vs.（19.94±5.52）μmol/L]、膽堿酯酶[（3043.55±141.23）mmol/L vs.（2894.42±169.52）mmol/L]明顯改善，差異有統計學意義（P <0.05）；腎功能的差異無統計學意義（P >0.05）。組內比較，治療後各項指標均明顯好于治療前（P <0.05）。髮熱、肝性腦病、血壓下降等不良反應髮生率也無明顯差異（P >0.05）。結論補氣活血利水方聯閤腹水濃縮迴輸治療可以明顯提高肝硬化頑固性腹水的臨床療效。
목적：평개보기활혈이수방약연합자체복수초려농축회수치료간경화완고성복수적림상료효。방법장90례을간간경화합병완고성복수환자수궤분위관찰조여대조조，매조45례，균접수상규치료화복수농축회수치료，관찰조환자가용보기활혈이수방약。결과관찰조화대조조적총유효솔분별위88.9%화64.4%（P <0.05）。치료후，관찰조교대조조적병안산안기전이매[（44.40±13.10)U/L vs.（56.90±15.50）U/L]、백단백[（33.04±3.13）g/L vs.（30.94±3.52）g/L]、총담홍소[（39.04±8.13）μmol/L vs.（52.94±9.52）μmol/L]、직접담홍소[（16.04±4.13）μmol/L vs.（19.94±5.52）μmol/L]、담감지매[（3043.55±141.23）mmol/L vs.（2894.42±169.52）mmol/L]명현개선，차이유통계학의의（P <0.05）；신공능적차이무통계학의의（P >0.05）。조내비교，치료후각항지표균명현호우치료전（P <0.05）。발열、간성뇌병、혈압하강등불량반응발생솔야무명현차이（P >0.05）。결론보기활혈이수방연합복수농축회수치료가이명현제고간경화완고성복수적림상료효。
Objective To evaluate the clinical efficacy of buqi huoxue lishui decoction combined with reinfusion of concentrated ascites in the treatment of refractory cirrhosis ascites. Methods Ninety cases of hepatitis B assaciated liver cirrhosis with refractory ascites were randomly divided into the observation group and the control group, both received con-ventional therapy and ascites reinfusion treatment, while the observation group was treated with the combination of buqi huoxue lishui decoction. Results The total response rate of the observation group and the control group was 88.9% and 64.4%(P < 0.05). After treatment, the liver function tests in the observation group were better than those of the control group, ALT[(44.40±13.10)U/L vs. (56.90±15.50)U/L], ALB[(33.04±3.13)g/L vs. (30.94±3.52)g/L], T-BIL[(39.04±8.13)μmol/L vs. (52.94±9.52)μmol/L]. D-BIL [(16.04±4.13)μmol/L vs. (19.94±5.52)μmol/L], CHE [(3 043.55±141.23) mmol/L vs. (2 894.42±169.52)mmol/L], P < 0.05. The liver function tests after therapy in each group were better than those of the pre-therapy (P<0.05 ). While there were no significant differences in renal function and adverse reactions (fever, hepatic encephalopathy, blood pressure decline) between the two groups after therapy (P >0.05). Conclusion Buqi huoxue lishui decoction combined with reinfusion of concentrated ascites can significantly improve the clinical efficacy of liver cirrhosis with refractory ascites.
